NSF/FDA SIR: Numerical heart model for irreversible electroporation ablation

NSF/FDA SIR:不可逆电穿孔消融的数字心脏模型

基本信息

项目摘要

Traditional cardiac ablation is a medical procedure that uses thermal energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats in atrial fibrillation (AF) patients. Non-thermal irreversible electroporation (IRE) ablation devices use short but strong electrical fields to create permanent pores in heart cells and are currently under safety and effectiveness review by the Center for Devices and Radiological Health (CDRH) at the Food and Drug Administration (FDA). In this project, a first-of-its-kind numerical IRE ablation heart model will be developed using quantifiable measurements of cell death and electrical properties of heart tissue to predict the size of ablation zone for a particular set of ablation pulse parameters. This model has the potential to decrease clinical and animal testing in the IRE device development, inform the FDA regulatory review process and ultimately accelerate AF patients access to innovative, safe and effective devices. The work will partner faculty and students at Virginia Tech (VT) and regulatory scientists at the CDRH/FDA.The goal of this project is to develop a numerical three-dimensional heart model on COMSOL Multiphysics with a representative geometry of heart tissue suitable for simulation of reversible, irreversible electroporation and thermal damage effects in pulsed electric field cardiac ablation. The model will use electric field thresholds of electroporation obtained from human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and dynamic conductivity of cardiac tissues measured in ex vivo porcine heart to inform a modified Laplace equation to determine electric potential distribution of a two-needle electrode setup. The model will be validated with limited ex vivo studies to confirm the capability of the numerical model to predict lesion volume in tissues using a large animal tissue model. Therefore, using the novel in silico-in vitro approach, Virginia Tech and the FDA will develop a numerical heart model for irreversible electroporation ablation, producing a scalable tool that can be extended to predicting IRE ablation treatments of other organs with varied electrode arrays. Successful accomplishment of this project will address current gaps in fundamental and regulatory knowledge, provide robust tool for optimization of IRE pulse parameters for cardiac ablation device development, advance understanding of IRE technology for AF treatment, and help address an urgent public health need for 2.7-6.1 million Americans affected by this common cardiac arrhythmia that can lead to heart failure and stroke.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
传统的心脏消融是一种使用热能破坏一小块心脏组织的医疗程序,这种组织会导致心房颤动(AF)患者出现快速而不规则的心跳。非热不可逆电穿孔(IRE)消融设备使用短但强的电场在心脏细胞中形成永久性毛孔,目前正在接受食品和药物管理局(FDA)设备和放射健康中心(CDRH)的安全性和有效性审查。在这个项目中,我们将利用细胞死亡和心脏组织电特性的可量化测量来建立首个此类数值消融心脏模型,以预测一组特定消融脉冲参数的消融区域的大小。这种模式有可能减少IRE设备开发中的临床和动物试验,为FDA的监管审查过程提供信息,并最终加速房颤患者获得创新、安全和有效的设备。这项工作将与弗吉尼亚理工大学(VT)的教职员工和学生以及CDRH/FDA的监管科学家合作。该项目的目标是开发一个基于COMSOL多物理的三维心脏数值模型,该模型具有心脏组织的典型几何形状,适合模拟脉冲电场心脏消融中的可逆、不可逆电穿孔和热损伤效应。该模型将使用从人诱导多能干细胞来源的心肌细胞(hiPSC-CM)获得的电穿孔的电场阈值和在体外猪心脏中测量的心脏组织的动态电导率来提供修正的拉普拉斯方程,以确定两针电极装置的电位分布。该模型将通过有限的体外研究进行验证,以证实该数值模型使用大型动物组织模型预测组织中病变体积的能力。因此,弗吉尼亚理工大学和FDA将利用这一新的体外硅方法,开发一个用于不可逆电穿孔消融的心脏数值模型,产生一个可扩展的可扩展工具,用于预测具有不同电极阵列的其他器官的IRE消融治疗。该项目的成功完成将解决目前基础和监管知识方面的空白,为心脏消融设备开发的IRE脉冲参数优化提供强大的工具,增进对用于房颤治疗的IRE技术的了解,并帮助解决270万至610万受这种可能导致心力衰竭和中风的常见心律失常影响的美国人的迫切公共卫生需求。该奖项反映了NSF的法定使命,并通过使用基金会的智力优势和更广泛的影响审查标准进行评估,被认为值得支持。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rafael Davalos其他文献

Rafael Davalos的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rafael Davalos', 18)}}的其他基金

Planning IUCRC Virginia Tech: Center for Cyber-Physical Systems for the Hospital Operating Room (CyBHOR)
规划 IUCCRC 弗吉尼亚理工大学:医院手术室网络物理系统中心 (CyBHOR)
  • 批准号:
    1747768
  • 财政年份:
    2018
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
U.S.-Australia Emerging Cancer Biomedical Technologies Workshop
美国-澳大利亚新兴癌症生物医学技术研讨会
  • 批准号:
    1735665
  • 财政年份:
    2017
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
I-Corps: Translation of High Frequency Irreversible Electroporation (H-FIRE) for Human Clinical Applications via the Veterinary Oncology Market
I-Corps:通过兽医肿瘤学市场将高频不可逆电穿孔 (H-FIRE) 转化为人类临床应用
  • 批准号:
    1265105
  • 财政年份:
    2012
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
CAREER: An experimental and numerical investigation of the biophysical processes of pulsed electric field induced irreversible electroporation for Glioblastoma Multiforme
职业:脉冲电场诱导不可逆电穿孔治疗多形性胶质母细胞瘤的生物物理过程的实验和数值研究
  • 批准号:
    1055913
  • 财政年份:
    2011
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
Combinatorial Brain Cancer Therapy through Irreversible Electroporation and Carbon Nanotubes
通过不可逆电穿孔和碳纳米管的组合脑癌治疗
  • 批准号:
    0933335
  • 财政年份:
    2009
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
BBSI: Summer Institute for Quantitative and Integrative Bioengineering (SIQIB)
BBSI:定量与综合生物工程夏季学院(SIQIB)
  • 批准号:
    0609225
  • 财政年份:
    2006
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Continuing Grant

相似国自然基金

FDA上市药物库筛选鉴定靶向治疗ARID1A缺陷型结直肠癌的合成致死效应及分子机制研究
  • 批准号:
    82373165
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
多维互质结构FDA雷达稀疏空时距自适应处理研究
  • 批准号:
    61771317
  • 批准年份:
    2017
  • 资助金额:
    62.0 万元
  • 项目类别:
    面上项目
基于FDA标记畸胎瘤细胞联合人胎盘屏障体外模型建立中药胚胎毒性评价体系的研究
  • 批准号:
    81573740
  • 批准年份:
    2015
  • 资助金额:
    63.0 万元
  • 项目类别:
    面上项目

相似海外基金

NSF/FDA SiR: Pulse Oximetry Measurement Errors Correlated with Patient Skin Pigmentation: Optical Mechanisms and Effect Multipliers
NSF/FDA SiR:与患者皮肤色素沉着相关的脉搏血氧饱和度测量误差:光学机制和效应乘数
  • 批准号:
    2229356
  • 财政年份:
    2023
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
NSF FDA/SiR: Development of eeDAP microscopy platform software, validation data, and statistical methods to assess performance of candidate Software as a Medical Device (SaMD)
NSF FDA/SiR:开发 eeDAP 显微镜平台软件、验证数据和统计方法,以评估候选软件作为医疗设备 (SaMD) 的性能
  • 批准号:
    2326317
  • 财政年份:
    2023
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
NSF/FDA SiR: A Nonclinical Testing Tool for Wearable Photoplethysmography-Based Blood Pressure Monitoring Devices
NSF/FDA SiR:用于基于光电体积描记法的可穿戴血压监测设备的非临床测试工具
  • 批准号:
    2325722
  • 财政年份:
    2023
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
NSF/FDA SiR: Validation and Standardization of Melanometry as a Quantitative Tool for Clinical Evaluation of Racial Disparities in Biophotonic Devices
NSF/FDA SiR:黑素测定法作为生物光子设备种族差异临床评估定量工具的验证和标准化
  • 批准号:
    2326485
  • 财政年份:
    2023
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
NSF/FDA SIR: Robust, Reliable, and Trustworthy Regulatory Science Tool for Stroke Recovery Assessment using Hybrid Brain-Muscle Functional Coupling Analysis
NSF/FDA SIR:使用混合脑-肌肉功能耦合分析进行中风恢复评估的稳健、可靠且值得信赖的监管科学工具
  • 批准号:
    2229697
  • 财政年份:
    2022
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
NSF/FDA SIR: 3D Human Stem Cell Cardiac Model for Cardiac Electrophysiology Medical Device Safety Assessment
NSF/FDA SIR:用于心脏电生理学医疗器械安全评估的 3D 人体干细胞心脏模型
  • 批准号:
    2129369
  • 财政年份:
    2022
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
NSF/FDA SIR: Towards the Establishment of a Validation Framework for Wearable Motion Analysis Systems: Development and Evaluation of an Open-Design Sync Platform
NSF/FDA SIR:建立可穿戴运动分析系统的验证框架:开放式设计同步平台的开发和评估
  • 批准号:
    2229538
  • 财政年份:
    2022
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
NSF/FDA SIR: Assessing the Photocytotoxicity and Photochemistry of New Emerging Fluorophores
NSF/FDA SIR:评估新兴荧光团的光细胞毒性和光化学
  • 批准号:
    2037815
  • 财政年份:
    2021
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
NSF/FDA SIR: Designing for Degradation: A framework for Predicting in vivo Degradation and Mechanical Property Changes in Degradable Polymers
NSF/FDA SIR:降解设计:预测可降解聚合物体内降解和机械性能变化的框架
  • 批准号:
    2129615
  • 财政年份:
    2021
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
NSF/FDA SIR: Focused ultrasound and microbubbles for transport of therapeutics across blood brain barrier: A cellular model
NSF/FDA SIR:用于跨血脑屏障运输治疗药物的聚焦超声和微泡:细胞模型
  • 批准号:
    2037849
  • 财政年份:
    2021
  • 资助金额:
    $ 9.73万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了